Researchers at the University of Copenhagen have identified a promising new drug target for weight loss which could revolutionise treatment for millions of people with obesity and type 2 diabetes. The ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its year-end outlook. Wall Street wasn't cheery about that.

The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...